InstalabLoading...
InstalabLoading...
If you have nagging allergy symptoms that flare in damp buildings, around compost or wood, or after time outdoors, the usual suspects (dust mites, pet dander, pollen, common molds) get most of the attention. Trichoderma viride is a less commonly tested mold that grows on decaying wood, soil, and damp indoor materials, and it sometimes appears on extended fungal allergy panels.
This test looks for an antibody called IgE (immunoglobulin E) in your blood that specifically recognizes Trichoderma viride. A positive result means your immune system has been primed to react to this mold. Whether that reaction is driving your symptoms depends on the rest of your clinical picture.
IgE is the antibody class your body makes when it develops an allergy. Your immune system can make IgE against pollen, food, animal dander, or, as in this case, mold proteins. When you encounter the mold again, that IgE triggers cells in your nose, lungs, and skin to release chemicals like histamine, which produce the symptoms you feel.
This test does not measure whether you currently have mold growing in your body or your home. It measures whether your immune system has built up Trichoderma viride (TV) specific antibodies, which is a marker of sensitization. Sensitization means your body is primed to react. It does not always mean you will have symptoms when exposed.
Mold sensitization, when measured as a group rather than by individual species, is consistently linked with worse respiratory disease. In a study of 551 children with asthma, those sensitized to mold had lower lung function (forced expiratory volume in the first second of 86.9% of predicted, compared with 92.0% to 93.4% in non-sensitized children) and far greater airway twitchiness on a methacholine challenge test (a test that measures how easily airways constrict). The threshold dose that triggered narrowing was about 16 to 28 times lower in mold-sensitized children, indicating much more reactive airways.
In a Singaporean and Malaysian study of more than 9,000 adults, sensitization to airborne fungi was linked to higher odds of having asthma and allergic rhinitis. Sensitization to Curvularia, for example, was associated with about 1.66 times the odds of asthma. Mold-sensitized people with asthma also reported more wheezing and more flares.
Older work specifically using extended mold panels in 121 asthmatic children showed that adding less common molds to standard testing, including Trichoderma, uncovered patients who had IgE reactions that the standard panel missed. Many of those children reacted to seven or more molds at once. This is the most direct human evidence that Trichoderma can be part of a meaningful allergy picture, although the study did not break out how often Trichoderma alone was positive or how strongly it predicted symptoms.
In adults with chronic obstructive pulmonary disease (COPD, a long-term lung condition that makes breathing difficult), a study of 446 patients identified a subgroup with high fungal IgE sensitization. This group had the worst outcomes: lower lung function, more symptoms, and frequent disease flares. Trichoderma viride was not specifically singled out, but the pattern reinforces that fungal IgE sensitization in general carries clinical weight.
For people without diagnosed lung disease, broader inhalant IgE sensitization also predicts future trouble. In a Danish population study pooling five cohorts (14,849 people, median follow-up 11.3 years), people sensitized to inhalant allergens had about 2.26 times the risk of developing asthma and roughly 20% higher risk of pneumonia, even after adjustment for age, sex, smoking, body weight, and other factors. In never-smokers, the asthma risk rose to 3.17 times. These data are about inhalant allergens as a group, not Trichoderma viride specifically, but they show why catching IgE sensitization early can matter.
There are two main ways to measure allergic sensitization: a skin prick test done in an allergist's office, and a blood test for specific IgE like this one. They overlap but do not fully agree. In a study of 2,646 people, skin prick testing was more sensitive for several common allergens, with 15% to 28% of patients positive only on the skin test, while 2% to 8% were positive only on blood IgE testing.
For fungal allergies specifically, the agreement between skin testing and blood IgE for any given mold is only 14% to 56%. That is why allergy specialists often use both, and why a single negative result on a standard panel does not rule out mold sensitization. If your symptoms point toward mold and your usual labs are clean, an extended panel that includes less common species like Trichoderma viride can fill in gaps.
Trichoderma viride specific IgE is a research and clinical exploratory marker without standardized population thresholds in major guidelines. Labs typically use the same general framework that applies to other allergen specific IgE assays. The ranges below reflect that general framework. Your lab's exact cutoffs may differ slightly, and a result needs to be interpreted alongside your symptoms and exposure history.
| Class | Range (kU/L) | What It Suggests |
|---|---|---|
| Negative | Less than 0.10 | No detectable IgE sensitization to this mold |
| Very low | 0.10 to 0.34 | Below the conventional sensitization threshold; clinical relevance unclear |
| Low positive | 0.35 to 0.69 | Sensitization detected; correlate with symptoms and exposure |
| Moderate to high positive | 0.70 and above | Stronger sensitization; more likely to be clinically relevant if symptoms align |
What this means for you: a positive result does not by itself diagnose a mold allergy. The number tells you whether your immune system recognizes Trichoderma viride. The diagnosis comes from connecting that signal to your actual symptoms and the environments you spend time in.
A single IgE reading is a snapshot. Allergen specific IgE levels can drift as your exposures change, after illnesses, or in response to treatments like allergen immunotherapy. The most useful information often comes from comparing results over time, in the same lab, using the same assay.
A practical approach: get a baseline if you suspect mold is contributing to your symptoms. If you make significant environmental changes (remediating a damp basement, replacing carpets, moving), retest in 6 to 12 months to see whether your sensitization is trending down. If you start allergen immunotherapy targeting fungi, retest annually to track the immune response. Use the trend, not any single number, to judge whether your interventions are working.
A positive Trichoderma viride IgE is most useful when paired with the rest of the picture. The first step is symptom mapping: do your nasal, sinus, eye, skin, or breathing symptoms get worse in damp environments, around decaying wood or compost, or in specific buildings? If yes, the result is more likely to be clinically meaningful.
Companion testing usually includes a broader fungal IgE panel (Alternaria, Aspergillus, Cladosporium, Penicillium) and total IgE, which provides context for any single allergen result. If you have asthma symptoms, lung function testing and a workup for allergic bronchopulmonary disease may be appropriate. If symptoms are severe, persistent, or hard to pin down, an allergist or immunologist can combine your blood IgE results with skin testing and history to build a complete picture and discuss options like environmental control or, in select cases, allergen immunotherapy.
In a US analysis of more than 1.6 million people tested, fungal allergen sensitization was more common in males, teenagers, and people with atopic dermatitis (eczema) or asthma, and varied by region. In children, sensitization rates rise with age and are influenced by climate and indoor environment. None of these data are Trichoderma viride specific, but they tell you the kinds of people in whom mold IgE positivity is more likely.
Evidence-backed interventions that affect your Trichoderma Viride Mold IgE level
Trichoderma Viride Mold IgE is best interpreted alongside these tests.